Bevacizumab Biosimilar Nears Market As Amgen Files First At FDA
Executive Summary
What is believed to be the first biosimilar version of Roche's Avastin to be filed with the US FDA has come from Amgen working in collaboration with Allergan, with the two companies heading a dozen-strong group of companies racing to develop versions of the monoclonal antibody.
You may also be interested in...
Amgen/Allergan Target Lucrative Avastin Market With Another Biosimilar Filing
Amgen and Allergan have filed an EU marketing authorization application for their biosimilar version of Roche’s monoclonal antibody product for cancer, Avastin (bevacizumab). In doing so, they join a growing number of biosimilars awaiting approval by the European authorities.
Amgen/Allergan Target Lucrative Avastin Market With Another Biosimilar Filing
Amgen and Allergan have filed an EU marketing authorization application for their biosimilar version of Roche’s monoclonal antibody product for cancer, Avastin (bevacizumab). In doing so, they join a growing number of biosimilars awaiting approval by the European authorities.
Stockwatch: The Post-Truth Biopharma Rally
The post-election rally in biopharmaceutical stocks was driven partly by hopes that drug pricing pressures will evaporate. However, this is a facet of post-truth culture rather than a real possibility. As Teva, Mylan and maybe Novartis have demonstrated, more is less when it comes to generic exposure.